Blood Cancer News and Research

RSS

Researchers to use $1 million grant for improving blood cancer diagnosis and treatment

Adelaide researchers will use a $1 million grant to improve the diagnosis and treatment of blood cancers, which kill 16 Australians every day.

28 Sep 2022

UVA's new discovery could help ramp up production of blood-clotting platelets

A new discovery from the University of Virginia School of Medicine could let doctors ramp up production of blood-clotting platelets on demand, a timely finding following the Red Cross' declaration earlier this year of a national blood "crisis."

23 Sep 2022

Better physical fitness reduces frailty risk in patients with chronic lymphocytic leukemia

Increased levels of exercise could help reduce frailty in patients with the most common form of leukemia, chronic lymphocytic (CLL), according to new research from the University of Surrey.

21 Sep 2022

Study shows encouraging therapeutic options for patients with relapsed multiple myeloma

Mount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple myeloma after first-line treatment with bispecific antibodies fails.

1 Sep 2022

Immune cells beyond CAR-T cells affect the durability of response to BCMA CAR T therapy in myeloma

Patients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer markers of immune cell exhaustion, and distinct changes to immune cell populations were more likely to have longer progression-free survival (PFS) after treatment with BCMA-targeted T-cell therapy.

30 Aug 2022

Anonymous $5.75 million gift will enable UVA to fight against rare blood cancers

A gift of more than $5.75 million from anonymous donors will allow UVA Cancer Center to speed the development of new treatments for rare blood cancers and provide more patients with these cancers access to cutting-edge clinical trials.

29 Aug 2022

New approach using CRISPR can engineer massive quantities of cells for therapeutic applications

A new variation of the CRISPR-Cas9 gene editing system makes it easier to re-engineer massive quantities of cells for therapeutic applications.

25 Aug 2022

The QCOVID4 algorithm developed using data from the Omicron wave identifies those at highest risk of severe COVID-19 outcomes

A recent article illustrated the derivation and validation of the QCOVID4 risk determination algorithm for predicting COVID-19 hospitalization and death risk in England.

18 Aug 2022

People with blood-related cancers more likely to experience COVID breakthrough infections

Individuals with blood-related cancers are more likely to experience a COVID-19 infection even after being vaccinated, a University of Kansas Cancer Center study has found.

12 Aug 2022

New 'decoy receptor' molecules inhibit growth of multiple myeloma and diffuse large B cell lymphoma in mice

Researchers at Stanford University have developed "decoy receptor" molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice.

26 Jul 2022

Improving the immune defenses against blood cancer

For patients with lymphoma, multiple myeloma, or certain types of leukemia, treatment with chimeric antigen receptor T cells (CAR T cells) is sometimes the last chance of overcoming the cancer.

22 Jul 2022

In America, cancer patients endure debt on top of disease

Jeni Rae Peters would make promises to herself as she lay awake nights after being diagnosed with breast cancer two years ago.

9 Jul 2022

Rare Cells Capable of Transforming into Leukemia may Provide new Insight into Leukemic Landscape

In our latest interview, News Medical speaks to Adam G. Schrum, PhD, Associate Professor of Molecular Microbiology & Immunology and Surgery at the University of Missouri, about how dysfunction in an unusual type of thymocyte cell may develop into leukemia in some patients.

8 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

Unusual type of thymocyte cells capable of transforming into blood cancer discovered

Dysfunction involving an unusual type of thymocyte cell found in small amounts in every person may be the reason why some people develop a form of leukemia called T-cell acute lymphoblastic leukemia (T-ALL) that affects more than 6,000 Americans each year.

28 Jun 2022

100 million people in America are saddled with health care debt

Elizabeth Woodruff drained her retirement account and took on three jobs after she and her husband were sued for nearly $10,000 by the New York hospital where his infected leg was amputated.

16 Jun 2022

Researchers identify a signature of three genes linked to positive response to blood cancer therapy

Mount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.

16 Jun 2022

Researchers create first comprehensive functional map of genes expressed in human cells

The Human Genome Project was an ambitious initiative to sequence every piece of human DNA. The project drew together collaborators from research institutions around the world, including Whitehead Institute, and was finally completed in 2003.

9 Jun 2022

COVID-19 vaccination may offer less effective and shorter-lasting protection for some cancer patients

A study co-led by the Universities of Oxford, Birmingham and Southampton and the UK Health Security Agency (UKHSA), published in Lancet Oncology today by the UK Coronavirus Cancer Evaluation Project, has found that while COVID-19 vaccination is effective in most cancer patients, the level of protection against COVID-19 infection, hospitalization and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

7 Jun 2022

Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.

2 Jun 2022